

**ESOT SOCIETY FOR ORGAN
TRANSPLANTATION**
AMSTERDAM

ANNUAL ACCOUNTS 2023

BALANCE SHEET AS AT 31 DECEMBER 2023

After proposal profit appropriation

ASSETS

| | <u>2023</u> | <u>2022</u> |
|----------------------------------|-------------------------|-------------------------|
| | EUR | EUR |
| CURRENT ASSETS | | |
| RECEIVABLES | | |
| Receivables from group companies | 1,079,330 | 675,087 |
| Other | <u>37,993</u> | <u>16,587</u> |
| | 1,117,323 | 691,674 |
| CASH AT BANK AND IN HAND | <u>3,537,727</u> | <u>3,604,846</u> |
| Total current assets | 4,655,050 | 4,296,520 |
| | | |
| TOTAL ASSETS | <u><u>4,655,050</u></u> | <u><u>4,296,520</u></u> |

LIABILITIES

| | <u>2023</u> | | <u>2022</u> | |
|--|----------------|------------------|----------------|------------------|
| | EUR | EUR | EUR | EUR |
| CONTINUATION RESERVES | | 4,466,080 | | 4,088,790 |
| SHORT-TERM LIABILITIES | | | | |
| Trade creditors | 9,626 | | 8,339 | |
| Other liabilities and accrued expenses | <u>179,344</u> | | <u>199,391</u> | |
| | | 188,970 | | 207,730 |
| | | <u>4,655,050</u> | | <u>4,296,520</u> |

PROFIT AND LOSS ACCOUNT FOR THE YEAR 2023

| | Budget 2023 | | 2023 | | 2022 | |
|---|-----------------|-----------------|-----------------|----------------|--------------|-----------------|
| | EUR | EUR | EUR | EUR | EUR | EUR |
| INCOME | | 1,032,848 | | 1,017,628 | | 147,390 |
| Direct costs | | 1,644,736 | | 929,898 | | 167,116 |
| Contribution margin | | <u>-611,888</u> | | <u>87,730</u> | | <u>-19,726</u> |
| Salaries and wages | 418,800 | | 537,244 | | 11,959 | |
| Consultants | 360,000 | | 375,118 | | - | |
| Social security premiums | 130,770 | | 162,955 | | - | |
| Other staff expenses | 10,850 | | 12,436 | | - | |
| Depreciation | 2,250 | | 3,080 | | - | |
| Housing expenses | 21,400 | | 21,667 | | - | |
| Governance expenses | 173,400 | | 132,520 | | - | |
| Marketing and Communication | 114,143 | | 115,972 | | - | |
| Other operating expenses | <u>210,402</u> | | <u>301,818</u> | | <u>7,549</u> | |
| | 1,442,015 | | 1,662,810 | | 19,508 | |
| Recharged to activities and to ESOT Foundation | <u>-602,352</u> | | <u>-766,578</u> | | <u>-</u> | |
| TOTAL OPERATING EXPENSES | | <u>839,663</u> | | <u>896,232</u> | | <u>19,508</u> |
| OPERATING RESULT | | -1,451,551 | | -808,502 | | -39,234 |
| Result from ESOT Foundation | | 1,907,851 | | 1,151,227 | | -228,085 |
| Financial income and expense | | <u>-</u> | | <u>34,565</u> | | <u>-10,176</u> |
| NET RESULT | | <u>456,300</u> | | <u>377,290</u> | | <u>-277,495</u> |

NOTES TO THE FINANCIAL STATEMENTS

GENERAL

ACTIVITIES

European Society for Organ Transplantation was incorporated on 27 February 2009 and has its registered office in Amsterdam (KvK nr. 34329686). The Society's main activities started in 2011 and are:

- furthering and encouragement of knowledge and research concerning donation and/or transplantation;
- creating a scientific forum for activities in the field of donation and/or transplantation.

ESOT is registered as a charity (Algemeen Nut Beogende Instelling: ANBI) in the Netherlands.

As part of its strategic development, ESOT continued in 2023 to carry out key activities to build on the credibility of our organization which are:

Funding of a pan-European and multi-organ registry (project start in 2021)

ESOT is dedicated to the pursuit of clinical and research excellence and improving patient outcomes. Its core mission is to promote sharing of scientific information and building of evidence-based international practice, policies and medical guidelines. To this aim, ESOT has decided to strengthen its engagement in the collection of data on organ transplantation, and has launched a platform to host pan-European registries on transplant recipients and living donors.

Industry sponsored projects

ESOT has been collaborating with industry partners to develop projects that contribute to our mission of advancing the field of organ transplantation. These projects, developed in partnership with single industry partners, have helped us diversify our income streams while providing valuable scientific and educational resources to the ESOT community. By working with industry partners, we have been able to build on our existing programs and initiatives, bringing new perspectives and expertise to our work. These partnerships have been an essential part of our efforts to support the development of new treatments and technologies, as well as to promote innovation and excellence in the field of organ transplantation.

International and Global stakeholders

ESOT strengthened its position as a leader in the field of organ transplantation by partnering with major global health organizations such as the European Centre for Disease Prevention and Control (ECDC), the World Health Organization (WHO), and the European Medicines Agency (EMA). We joined their working groups and actively participated in discussions and initiatives

aimed at placing transplantation at the highest level of political agendas. These partnerships have enabled us to increase our capacity building and advocacy efforts, while also providing valuable opportunities for networking and collaboration with other leaders in the healthcare industry. ESOT has also implemented new barter agreements with National Societies to attract new members to our community.

Educational courses and scientific meetings

ESOT resumed several in-person educational courses. While the COVID-19 pandemic continued to pose challenges, we recognized the importance of offering in-person educational opportunities for our members and the wider transplant community. Despite the uncertainty caused by the pandemic, we saw strong demand for these courses, with registrations coming in later than usual. As a result, it was difficult to forecast attendance and plan accordingly. Additionally, we faced increased costs from suppliers due to the pandemic's impact on the hospitality industry. Despite these challenges, the feedback we received from attendees and the value of these courses demonstrated the need for in-person educational opportunities. The full calendar of 2022 events can be found on the ESOT website.

Launch of a Task Force for the Development of European Guidelines and Recommendations

The development of guidelines and recommendations is an important investment for ESOT as it helps to establish best practices and standardize care in the field of organ transplantation. Guidelines and recommendations are developed based on the best available evidence and expert consensus and are intended to provide clinicians and healthcare providers with clear, evidence-based guidance on how to diagnose, manage, and treat patients with various conditions related to transplantation. By establishing a dedicated task force for this purpose, ESOT is better equipped to provide leadership in the development of guidelines and recommendations that reflect the latest advances in the field. This investment demonstrates our commitment to promoting excellence and innovation in the field of transplantation, while also providing valuable resources to clinicians and healthcare providers around the world. Ultimately, these guidelines and recommendations help to improve patient outcomes and enhance the quality of care provided to transplant patients.

Fostering equality of access – Policy and advocacy

ESOT has continued to invest efforts in Policy and Advocacy work. This has been done through the engagement of a membership at the European Public Health Alliance, the participation of awareness campaigns and other public health efforts. These investments are aimed to shape the political and regulatory environment in which organ transplantation takes place. By advocating for policies that support the needs of transplant patients and healthcare providers, ESOT can help to ensure that the resources and support necessary for effective transplantation are available. Overall, investing in policy and advocacy work is important for ESOT because it helps to ensure that the needs of transplant patients and healthcare providers are represented at the highest levels of decision-making. By promoting policies and advocating for change, ESOT can help to improve the outcomes and experiences of transplant patients and promote the continued success of the field of organ transplantation.

ESOT ETPO x ESOT Education

Building on the policy and advocacy efforts ESOT fostered patient engagement because it recognizes the critical role that patients and their families play in the transplantation process. Patients are at the center of everything we do, and engaging with them as partners in their care can help to improve outcomes and enhance the overall transplant experience. It can also help to identify and address patient concerns and preferences, leading to improved patient satisfaction and quality of life. Additionally, engaging patients in research and quality improvement efforts can help to ensure that the perspectives and needs of patients are incorporated into these activities, leading to more relevant and impactful outcomes.

By investing in patient engagement, ESOT is demonstrating its commitment to putting patients first and recognizing their important role in the transplantation process. This investment can help to promote more effective and patient-centered care, improve outcomes, and ultimately lead to better long-term outcomes for transplant patients.

Transplant International

ESOT made a strategic decision to change publishers in 2021, opting for a new partner, Frontiers, which offers gold open access to our publication in Transplant International. This decision was driven by a desire to make our content more accessible to a wider audience and to stay at the forefront of emerging trends in scientific publishing. This change represents a significant investment in the future of scientific publications. Open access publishing models are becoming increasingly popular and are seen as a way to increase the visibility and impact of research. By embracing this model, ESOT is positioning itself as a leader in the field and ensuring that our content is accessible to a global audience.

ACCOUNTING POLICIES IN RESPECT OF THE VALUATION OF ASSETS AND LIABILITIES

GENERAL

The financial statements have been prepared according with the Dutch generally accepted accounting principles and are denominated in Euro.

The financial statements have been prepared by applying the historical cost convention. Unless disclosed otherwise in the accounting principles for the specific balance sheet item, assets and liabilities are presented at face value.

Income and expenses are accounted for on an accrual basis. Profit is only recognized when realized on the balance sheet date. Losses originating before the end of the financial year are taken into account if they have become known before preparation of the financial statements.

ACCOUNTS RECEIVABLE

Upon initial recognition the receivables are valued at fair value and then valued at amortized cost. The fair value and amortized cost equal the face value. Provisions deemed necessary for possible bad debt losses are deducted. These provisions are determined by individual assessment of the receivables.

ACCOUNTING POLICIES IN RESPECT OF RESULT DETERMINATION

NET TURNOVER

The net income shown in the profit and loss account is the revenue from sponsors through a support-foundation and grants received from third parties net of value added tax.

DIRECT COSTS

The direct costs are recognized at cost.

OTHER OPERATING EXPENSES

Expenses are based on the historical cost convention and attributed to the financial year to which they pertain

Amsterdam, June 2024

G.C. Oniscu
President of the Executive Committee

F. Dor
Treasurer